Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘Follow The Money’: Sweden’s Calliditas Plans US Listing

CEO Says NASDAQ Float Will Position Biotech Better Before Pivotal Readout

Executive Summary

Sweden’s Calliditas plans a US IPO to better position itself ahead of this year’s pivotal readout of its orphan drug Nefecon in inflammatory renal disease IgA nephropathy.

You may also be interested in...



$90m IPO Sets Up Sweden's Calliditas For Phase III Readout

The Stockholm-headquartered company has exceeded expectations with its IPO, and now faces the ‘big reveal’ for its lead asset Nefecon.

SwedenBio Snapshot Shows Vibrant Ecosystem

Sweden´s ecosystem for drug discovery and development is flourishing, seeded by academia, nurtured by incubators and funded from varied sources, 2020 report shows.

Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies

Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.   

Topics

Related Companies

UsernamePublicRestriction

Register

SC142263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel